Roivant Sciences Ltd (NAS:ROIV)
$ 12.71 0.02 (0.16%) Market Cap: 9.25 Bil Enterprise Value: 3.92 Bil PE Ratio: 2.25 PB Ratio: 1.81 GF Score: 61/100

Roivant Sciences Ltd at H.C. Wainwright BioConnect Investor Conference Transcript

May 02, 2023 / 05:00PM GMT
Release Date Price: $8.21 (-4.76%)
Doug Tsao
HC Wainwright - Analyst

Okay. Great. Welcome, everybody. Thanks for joining us today at the conference. I'm Doug Tsao, senior analyst at HC Wainwright. We're thrilled to have with us Roivant represented by Richard Pulik, the company's CFO.

So we'll sort of jump right into it because we only have 20 minutes.

So we're -- Richard, we're almost a year into the launch of VTAMA. Scripts got off to a really fast start. We saw a little bit of a slowdown at the end of '22 and the first couple of months of '23. Now, some of that was probably related to typical seasonality that you see in the first quarter at the start of the year.

We have seen a little bit of a step up again in the last few weeks. What do you think is the driver of that? And what are your perspectives on the near-term outlook for that product?

Richard Pulik
Roivant Sciences Ltd. - CFO

No. So I think, look, we have -- just to step back for folks who may not be familiar with the product. This is the first innovative topical that's been launched in the space in 25

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot